Monopar Therapeutics (MNPR) PT Raised to $128 at Barclays

August 13, 2026 5:38 AM

Barclays analyst Etzer Darout raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $128.00 (from $125.00) while maintaining a Overweight rating.

No results found